A new study suggests that drugs like Ozempic and Mounjaro may reduce dementia risk. Researchers at the University of Galway ...

With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent ...

An investigation has found at least 74 complaints have been made to hospital managers across England in the past 12 months.

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

The researchers estimate 6.5 billion years of life will likely be lost globally due to premature deaths caused by obesity’s negative health effects. The weight loss drugs could lead to a disruptive ...

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

As medications like 'Wegovy' and 'Ozempic' (GLP‑1 receptor agonists) become more common in weight‑loss strategies, US hospitals are emphasising that drugs alone aren’t enough; nutrition plays a ...

A new study has found that an anti-obesity drug called tirzepatide, which is sold under the names Mounjaro for diabetes and ...

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

Presented by AstraZeneca{beacon} Health Care Health Care   The Big Story CMS targets hospitals with site-neutral drug ruleThe ...